Effect of recombinant human brain natriuretic peptide combined with spironolactone and furosemide in the treatment of chronic heart failure and its influences on cardiac function,Gal-3 and GDF-15 levels
Objective To investigate the effect of recombinant human brain natriuretic peptide combined with spironolactone and furosemide in the treatment of chronic heart failure.Methods A total of 105 patients with chronic heart failure admitted from March 2022 to January 2023 were selected and divided into control group(52 cases,spironolactone+furosemide treatment)and observation group(53 cases,recombinant human brain natriuretic peptide treatment on the basis of the control group)by random number table method.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group(P＜0.05).After treatment,the left ventricular ejection fraction(LVEF)of the observation group was higher than that of the control group,and the levels of cardiac troponin Ⅰ(cTnⅠ)and N-terminal probrain natriuretic peptide(NT-proBNP)were lower than those of the control group(P＜0.05).After treatment,the levels of galactose lectin-3(Gal-3)and growth differentiation factor-15(GDF-15)in the observation group were lower than those in the control group(P＜0.05).After treatment,the 6-minute walking distance of the observation group was longer than that of the control group,and the Minnesota Living with Heart Failure Questionnaire(MLHFQ)score was lower than that of the control group(P＜0.05).Conclusion The recombinant human brain natriuretic peptide combined with spironolactone and furosemide in the treatment of chronic heart failure has satisfactory effect.It can effectively improve cardiac function,inhibit Gal-3 and GDF-15 levels,and improve patients'exercise tolerance and quality of life,which is worth promoting.
recombinant human brain natriuretic peptidespironolactonefurosemidechronic heart failurecardiac function
NETL
NSTL
万方数据
